Gland Pharma Ltd
NSE:GLAND

Watchlist Manager
Gland Pharma Ltd Logo
Gland Pharma Ltd
NSE:GLAND
Watchlist
Price: 1 460.3 INR -0.06% Market Closed
Market Cap: 240.6B INR

Gland Pharma Ltd
Investor Relations

Gland Pharma Ltd., an Indian company with a robust heritage, has made its mark in the global pharmaceutical landscape primarily through its adeptness in injectable medication. Founded in 1978 by P.V.N. Raju, the company’s journey has been one of steady ascension, characterized by a firm commitment to quality and innovation. Operating in a market where precision and reliability are paramount, Gland Pharma has specialized in the development and manufacturing of complex generic injectables, a niche that demands rigorous regulatory compliance and state-of-the-art manufacturing capabilities. With its extensive product portfolio, Gland Pharma serves a diverse range of therapeutic areas, including anti-coagulants, anti-biotics, and anti-virus medications, catering to hospitals and healthcare facilities worldwide. This strategic focus has enabled the company to build a reputable name in both domestic and international markets, becoming a critical supplier in the intricate supply chain of modern healthcare.

What distinguishes Gland Pharma from many contemporaries is its business model that hinges on backward integration and robust R&D capabilities. By taking charge of every aspect of production—from procuring raw materials to the final packaging—the company achieves cost efficiencies and ensures unwavering quality control. This integration extends beyond manufacturing, as Gland Pharma has cultivated strong relationships with strategic partners globally, facilitating its penetration into regulated markets such as the US, EU, and Australia. It harnesses these connections to distribute its products extensively while also acquiring ANDA (Abbreviated New Drug Application) approvals that cement its standing in these regions. Financially, Gland Pharma's revenue is largely derived from this steady export of generic injectables, riding on the ever-growing demand for affordable healthcare solutions. Through these strategic endeavors, the company encapsulates a blend of Indian manufacturing prowess and global pharmaceutical acumen, keeping its financial health robust and its market reach expansive.

Show more
Loading

Earnings Calls

2025 Q4
May 2, 2025
Show Transcript
Previous
Next
Coromandel's robust growth highlights strong market position and expansion plans.
2025 Q4
May 2, 2025

In Q4, Coromandel International showcased impressive growth with a total income of INR 5,114 crores, up 28% year-over-year, driven by strong demand across its sectors. The company anticipates high double-digit revenue growth for FY '26, bolstered by new product introductions and an expanding retail footprint. A final dividend of INR 9 per share was declared, with INR 3 as a special one-time payout. Notably, Coromandel is set to enhance its position in the crop protection sector through its acquisition of NACL Industries, which is expected to be finalized by Q2 FY '26.

Show Full Analysis

Management

Mr. Srinivas Sadu
CEO & Executive Chairman
No Bio Available
Mr. Ravi Shekhar Mitra
Chief Financial Officer
No Bio Available
Mr. Sampath Kumar Pallerlamudi
Company Secretary & Vice-President of Compliance & CSR
No Bio Available
Mr. Satnam Singh Loomba
Chief Operating Officer
No Bio Available
Mr. Ankit Gupta
Head of Investments, Strategy & Investor Relations
No Bio Available
Mr. Surinder Koul
Head of Domestic Marketing
No Bio Available
Mr. K Raghuramachandra Rao
Head of Quality
No Bio Available
Mr. R.V.R. Prabhakara Sastry
Senior Vice President of R&D
No Bio Available
Mr. Rong Wu
Chief Financial Controller
No Bio Available

Contacts

Address
TELANGANA
Hyderabad
Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads, D.P. Pally, Dundigal Gandimaisamma Mandal Medchal-Malkajgiri District
Contacts
+914030510999
www.glandpharma.com